Communiqués de presse

CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

Edwards Lifesciences to Host Investor Event in Conjunction With TCT